NU1433-10 RAR-M Therapeutics Ltd The Provision of Business Consultancy to Assist Commercialisation of University Research.
What the buyer wrote
Amyotrophic lateral sclerosis (ALS) - as with most other neurodegenerative diseases, including Alzheimer's and Parkinson's - is a major medical challenge and is having an ever-increasing impact upon the lives of patients, carers and indeed of society as a whole. Scientists at Durham (Chemistry Department) and Aberdeen Universities have recently designed, synthesised and identified a lead drug candidate with the potential for establishing a new treatment approach for ALS and with a longer-term potential of being effective for other neurodegenerative diseases. The technology is now being patented and we are ready to develop a commercial vehicle to drive the drug development programme forwa…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- NU1433-10 RAR-M Therapeutics Ltd The Provision of Business Consultancy to Assist Commercialisation of University Research.
- How they are buying
- The buyer did not say
- Type
- services
- Suitable for small firms
- The buyer says yes. What that is worth
- Work starts
- 30 Apr 2020
- Work ends
- 31 Dec 2020
- Kind of work
- Professional services
Who the buyer named
Natalie Morton was the named contact on this notice.